Copy to clipboard 
CONMED Sports Medicine Sales by Year
CONMED has been exploring the possibility of selling the company, according to a report from Bloomberg. Our chart of the month looks at the company’s sports medicine performance over the last 10 years.
While CONMED ended 2025 with $521.4 million in sports medicine sales, the company’s 10-year CAGR is 2.4%, which is about half that of the sports medicine market overall during that period. Performance has improved since 2021, but the company remains below the industry growth average.
CONMED accounted for approximately 8.4% of the sports medicine market in 2016, but fell to 6.9% by the end of 2025.
“From a pure number standpoint, we’ve lost market share,” said CONMED CEO Pat Beyer. “The good news is that with a platform like BioBrace, we’re still driving forward, and we’re on offense there. We continue to be seen as an innovative orthopedic company globally. So on one hand, we have lost market share this year. The numbers say that. On the other side, our innovation from new products continues to roll out and our BioBrace platform continues to put us in a good position going forward.”
Mike Matson, Senior Research Analyst at Needham & Company, floated Zimmer Biomet as a possible buyer if CONMED does decide to sell. We agree that the asset checks many boxes for Zimmer Biomet.
In early 2025, Zimmer Biomet said it was interested in buying “anything that happens in the ASC and anything that makes sense within SET.” The company also expressed interest in expanding outside its core orthopedic business as it seeks a WAMGR of 5% by the end of 2027, with that number needing to grow further by the end of 2030.
On the other hand, by the end of 2025, Zimmer Biomet seemed to pump the brakes on further acquisitions. CEO Ivan Tornos said the company was focused on managing its acquisitions of OrthoGrid, Paragon 28 and Monogram, on top of the disruption from its U.S. channel transformation. “Now is not the time to add more complexity,” he said.
CONMED Sports Medicine Sales by Year
CONMED has been exploring the possibility of selling the company, according to a report from Bloomberg. Our chart of the month looks at the company's sports medicine performance over the last 10 years.
While CONMED ended 2025 with $521.4 million in sports medicine sales, the company's 10-year...
CONMED Sports Medicine Sales by Year
CONMED has been exploring the possibility of selling the company, according to a report from Bloomberg. Our chart of the month looks at the company’s sports medicine performance over the last 10 years.
While CONMED ended 2025 with $521.4 million in sports medicine sales, the company’s 10-year CAGR is 2.4%, which is about half that of the sports medicine market overall during that period. Performance has improved since 2021, but the company remains below the industry growth average.
CONMED accounted for approximately 8.4% of the sports medicine market in 2016, but fell to 6.9% by the end of 2025.
“From a pure number standpoint, we’ve lost market share,” said CONMED CEO Pat Beyer. “The good news is that with a platform like BioBrace, we’re still driving forward, and we’re on offense there. We continue to be seen as an innovative orthopedic company globally. So on one hand, we have lost market share this year. The numbers say that. On the other side, our innovation from new products continues to roll out and our BioBrace platform continues to put us in a good position going forward.”
Mike Matson, Senior Research Analyst at Needham & Company, floated Zimmer Biomet as a possible buyer if CONMED does decide to sell. We agree that the asset checks many boxes for Zimmer Biomet.
In early 2025, Zimmer Biomet said it was interested in buying “anything that happens in the ASC and anything that makes sense within SET.” The company also expressed interest in expanding outside its core orthopedic business as it seeks a WAMGR of 5% by the end of 2027, with that number needing to grow further by the end of 2030.
On the other hand, by the end of 2025, Zimmer Biomet seemed to pump the brakes on further acquisitions. CEO Ivan Tornos said the company was focused on managing its acquisitions of OrthoGrid, Paragon 28 and Monogram, on top of the disruption from its U.S. channel transformation. “Now is not the time to add more complexity,” he said.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
